507 related articles for article (PubMed ID: 22722778)
1. Treatment of resistant glomerular diseases with adrenocorticotropic hormone gel: a prospective trial.
Bomback AS; Canetta PA; Beck LH; Ayalon R; Radhakrishnan J; Appel GB
Am J Nephrol; 2012; 36(1):58-67. PubMed ID: 22722778
[TBL] [Abstract][Full Text] [Related]
2. Acthar gel in the treatment of nephrotic syndrome: a multicenter retrospective case series.
Madan A; Mijovic-Das S; Stankovic A; Teehan G; Milward AS; Khastgir A
BMC Nephrol; 2016 Mar; 17():37. PubMed ID: 27036111
[TBL] [Abstract][Full Text] [Related]
3. Tacrolimus therapy in adults with steroid- and cyclophosphamide-resistant nephrotic syndrome and normal or mildly reduced GFR.
Li X; Li H; Ye H; Li Q; He X; Zhang X; Chen Y; Han F; He Q; Wang H; Chen J
Am J Kidney Dis; 2009 Jul; 54(1):51-8. PubMed ID: 19406543
[TBL] [Abstract][Full Text] [Related]
4. Treatment of nephrotic syndrome with adrenocorticotropic hormone (ACTH) gel.
Bomback AS; Tumlin JA; Baranski J; Bourdeau JE; Besarab A; Appel AS; Radhakrishnan J; Appel GB
Drug Des Devel Ther; 2011 Mar; 5():147-53. PubMed ID: 21448451
[TBL] [Abstract][Full Text] [Related]
5. Treatment of idiopathic FSGS with adrenocorticotropic hormone gel.
Hogan J; Bomback AS; Mehta K; Canetta PA; Rao MK; Appel GB; Radhakrishnan J; Lafayette RA
Clin J Am Soc Nephrol; 2013 Dec; 8(12):2072-81. PubMed ID: 24009220
[TBL] [Abstract][Full Text] [Related]
6. Incidence of remission and relapse of proteinuria, end-stage kidney disease, mortality, and major outcomes in primary nephrotic syndrome: the Japan Nephrotic Syndrome Cohort Study (JNSCS).
Yamamoto R; Imai E; Maruyama S; Yokoyama H; Sugiyama H; Nitta K; Tsukamoto T; Uchida S; Takeda A; Sato T; Wada T; Hayashi H; Akai Y; Fukunaga M; Tsuruya K; Masutani K; Konta T; Shoji T; Hiramatsu T; Goto S; Tamai H; Nishio S; Shirasaki A; Nagai K; Yamagata K; Hasegawa H; Yasuda H; Ichida S; Naruse T; Nishino T; Sobajima H; Tanaka S; Akahori T; Ito T; Terada Y; Katafuchi R; Fujimoto S; Okada H; Ishimura E; Kazama JJ; Hiromura K; Mimura T; Suzuki S; Saka Y; Sofue T; Suzuki Y; Shibagaki Y; Kitagawa K; Morozumi K; Fujita Y; Mizutani M; Shigematsu T; Kashihara N; Sato H; Matsuo S; Narita I; Isaka Y
Clin Exp Nephrol; 2020 Jun; 24(6):526-540. PubMed ID: 32146646
[TBL] [Abstract][Full Text] [Related]
7. Pharmacologic management of adult idiopathic nephrotic syndrome.
Alaniz C; Brosius FC; Palmieri J
Clin Pharm; 1993 Jun; 12(6):429-39. PubMed ID: 8403814
[TBL] [Abstract][Full Text] [Related]
8. Glomerular tip lesion: a distinct entity within the minimal change disease/focal segmental glomerulosclerosis spectrum.
Stokes MB; Markowitz GS; Lin J; Valeri AM; D'Agati VD
Kidney Int; 2004 May; 65(5):1690-702. PubMed ID: 15086908
[TBL] [Abstract][Full Text] [Related]
9. A modern approach to selectivity of proteinuria and tubulointerstitial damage in nephrotic syndrome.
Bazzi C; Petrini C; Rizza V; Arrigo G; D'Amico G
Kidney Int; 2000 Oct; 58(4):1732-41. PubMed ID: 11012907
[TBL] [Abstract][Full Text] [Related]
10. Cyclosporine in idiopathic nephrotic syndrome.
Ponticelli C
Immunopharmacol Immunotoxicol; 1993 Aug; 15(4):479-89. PubMed ID: 8227973
[TBL] [Abstract][Full Text] [Related]
11. The efficacy of cyclosporine A in adult nephrotic syndrome with minimal change disease and focal-segmental glomerulosclerosis: a multicenter study in Korea.
Lee HY; Kim HS; Kang CM; Kim SG; Kim MJ
Clin Nephrol; 1995 Jun; 43(6):375-81. PubMed ID: 7554521
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of primary nephrotic syndrome in elderly Japanese: retrospective analysis of the Japan Renal Biopsy Registry (J-RBR).
Yokoyama H; Sugiyama H; Narita I; Saito T; Yamagata K; Nishio S; Fujimoto S; Mori N; Yuzawa Y; Okuda S; Maruyama S; Sato H; Ueda Y; Makino H; Matsuo S
Clin Exp Nephrol; 2015 Jun; 19(3):496-505. PubMed ID: 25230687
[TBL] [Abstract][Full Text] [Related]
13. Leveraging melanocortin pathways to treat glomerular diseases.
Gong R
Adv Chronic Kidney Dis; 2014 Mar; 21(2):134-51. PubMed ID: 24602463
[TBL] [Abstract][Full Text] [Related]
14. Long-term ciclosporine A treatment in adults with minimal change nephrotic syndrome or focal segmental glomerulosclerosis.
Ittel TH; Clasen W; Fuhs M; Kindler J; Mihatsch MJ; Sieberth HG
Clin Nephrol; 1995 Sep; 44(3):156-62. PubMed ID: 8556831
[TBL] [Abstract][Full Text] [Related]
15. Clinical and morphological prognostic factors in membranous nephropathy: significance of focal segmental glomerulosclerosis.
Dumoulin A; Hill GS; Montseny JJ; Meyrier A
Am J Kidney Dis; 2003 Jan; 41(1):38-48. PubMed ID: 12500220
[TBL] [Abstract][Full Text] [Related]
16. [Effect of cyclosporin A on renal function in patients with glomerulonephritis].
Heering P; Schneider A; Grabensee B; Plum J
Dtsch Med Wochenschr; 2001 Oct; 126(40):1093-8. PubMed ID: 11588659
[TBL] [Abstract][Full Text] [Related]
17. Use of Rituximab as an Off-Label Medication in Glomerular Diseases: Clinical Perspective.
AlSahow A; Al-Muhaiteeb A; Nawar H; AlHelal B; AlYousef A; Abdallah E; AbuShall A; Elmekawi S; Meshal B; AlQallaf A; AlRajab H
Med Princ Pract; 2022; 31(2):133-141. PubMed ID: 35021170
[TBL] [Abstract][Full Text] [Related]
18. Effects of cyclosporin A on glomerular barrier function in the nephrotic syndrome.
Zietse R; Wenting GJ; Kramer P; Schalekamp MA; Weimar W
Clin Sci (Lond); 1992 Jun; 82(6):641-50. PubMed ID: 1320544
[TBL] [Abstract][Full Text] [Related]
19. Partial remission of resistant nephrotic syndrome after oral galactose therapy.
Kopač M; Meglič A; Rus RR
Ther Apher Dial; 2011 Jun; 15(3):269-72. PubMed ID: 21624074
[TBL] [Abstract][Full Text] [Related]
20. Treatment of nephrotic syndrome with adrenocorticotropic hormone (ACTH).
Bomback AS; Radhakrishnan J
Discov Med; 2011 Aug; 12(63):91-6. PubMed ID: 21878186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
